Zacks Research Forecasts Sanofi’s Q2 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities researchers at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for shares of Sanofi in a research note issued on Wednesday, February 19th. Zacks Research analyst K. Shah now forecasts that the company will post earnings per share of $0.93 for the quarter, down from their previous estimate of $0.94. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2025 earnings at $0.96 EPS, FY2025 earnings at $4.34 EPS, Q2 2026 earnings at $1.06 EPS and Q3 2026 earnings at $1.44 EPS.

SNY has been the topic of several other reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Up 0.6 %

NASDAQ SNY opened at $54.46 on Monday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a 50 day moving average price of $50.95 and a 200-day moving average price of $52.53. The company has a market capitalization of $138.21 billion, a P/E ratio of 21.87, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Institutional Trading of Sanofi

Several large investors have recently added to or reduced their stakes in SNY. Price T Rowe Associates Inc. MD lifted its holdings in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after acquiring an additional 5,091,304 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Sanofi during the 4th quarter valued at about $135,933,000. Boston Partners grew its position in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares during the period. Jennison Associates LLC boosted its stake in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after buying an additional 1,720,972 shares during the period. Finally, Magnetar Financial LLC boosted its position in shares of Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after buying an additional 1,705,148 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.